Cargando…

PI3K/mTOR Dual Inhibitor Pictilisib Stably Binds to Site I of Human Serum Albumin as Observed by Computer Simulation, Multispectroscopic, and Microscopic Studies

Pictilisib (GDC-0941) is a well-known dual inhibitor of class I PI3K and mTOR and is presently undergoing phase 2 clinical trials for cancer treatment. The present work investigated the dynamic behaviors and interaction mechanism between GDC-0941 and human serum albumin (HSA). Molecular docking and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hongqin, Ma, Yanjun, Zhang, Hongjie, Ma, Junyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413508/ https://www.ncbi.nlm.nih.gov/pubmed/36014303 http://dx.doi.org/10.3390/molecules27165071

Ejemplares similares

Binding of Citreoviridin to Human Serum Albumin: Multispectroscopic and Molecular Docking
por: Hou, Haifeng, et al.
Publicado: (2015)

Investigation of the Interaction Mechanism between Salbutamol and Human Serum Albumin by Multispectroscopic and Molecular Docking
por: Zhao, Ting, et al.
Publicado: (2020)

Biophysical Insights into Implications of PEG-400 on the α-Crystallin Structure: Multispectroscopic and Microscopic Approach
por: Shamsi, Anas, et al.
Publicado: (2020)

Studies of the Interaction between Isoimperatorin and Human Serum Albumin by Multispectroscopic Method: Identification of Possible Binding Site of the Compound Using Esterase Activity of the Protein
por: Ranjbar, Samira, et al.
Publicado: (2013)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer
por: Khalafi, Shayan, et al.
Publicado: (2021)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway
por: Liang, Chao, et al.
Publicado: (2021)

Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer
por: Cheng, Wei-Jie, et al.
Publicado: (2022)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
por: Ma, Jing, et al.
Publicado: (2023)

β-Carboline Silver Compound Binding Studies with Human Serum Albumin: A Comprehensive Multispectroscopic Analysis and Molecular Modeling Study
por: Alsalme, Ali, et al.
Publicado: (2018)

Exploring the Interaction of Cobalt Oxide Nanoparticles with Albumin, Leukemia Cancer Cells and Pathogenic Bacteria by Multispectroscopic, Docking, Cellular and Antibacterial Approaches
por: Arsalan, Niloofar, et al.
Publicado: (2020)

Binding and drug displacement study of colchicine and bovine serum albumin in presence of azithromycin using multispectroscopic techniques and molecular dynamic simulation
por: Wani, Tanveer A., et al.
Publicado: (2021)

Aflatoxin B(1) Induced Structural and Conformational Changes in Bovine Serum Albumin: A Multispectroscopic and Circular Dichroism-Based Study
por: Qureshi, Mohd Aamir, et al.
Publicado: (2021)

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro
por: Schoen, Leonie F., et al.
Publicado: (2022)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
por: Takeda, Takako, et al.
Publicado: (2016)

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
por: Luo, Leixuan, et al.
Publicado: (2023)

Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
por: Li, Jie, et al.
Publicado: (2021)

Insight into the Interaction Mechanism of HSA with Aztreonam: A Multispectroscopic and Computational Approach
por: Sabour, Amal A., et al.
Publicado: (2022)

(11)C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging
por: Han, Na, et al.
Publicado: (2019)

Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma
por: Pratap, Akshay, et al.
Publicado: (2023)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
por: Zhou, Yan, et al.
Publicado: (2017)

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors
por: Zhao, Bingbing, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer
por: Hung, Ming-Chun, et al.
Publicado: (2022)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice
por: Deinhardt-Emmer, Stefanie, et al.
Publicado: (2021)

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
por: Meng, Wei, et al.
Publicado: (2019)

Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation
por: Ma, Xiaodong, et al.
Publicado: (2019)

Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
por: Pitts, Todd M., et al.
Publicado: (2014)

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2018)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_315q8ek9aj51hvdgmcofhjpgm5